Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 8/20 | 0.86 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.82 |
| ▸ | DRD4 | P21917 | 4/20 | 0.82 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.82 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.82 |
| ▸ | TSHR | P16473 | 2/20 | 0.82 |
| ▸ | HTR1B | P28222 | 2/20 | 0.82 |
| ▸ | HTR7 | P34969 | 2/20 | 0.82 |
| ▸ | HTR2B | P41595 | 1/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.75 |
| ▸ | MEN1 | O00255 | 2/20 | 0.75 |
| ▸ | BLM | P54132 | 2/20 | 0.75 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | MTOR | P42345 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12677610 | 1.00 | HTR1A (0.86) | HTR1AADRA1ADRD4ADRA1DADRA1B | |
| SCHEMBL12677609 | 1.00 | HTR1A (0.86) | HTR1AADRA1ADRD4ADRA1DADRA1B | |
| SCHEMBL9605385 | 0.92 | HTR1A (1.00) | HTR1AADRA1ADRD4ADRA1DADRA1B | |
| SCHEMBL15722836 | 0.92 | HTR1A (0.84) | HTR1AADRA1ADRD4ADRA1DADRA1B | |
| SCHEMBL12677606 | 0.92 | HTR1A (1.00) | HTR1AADRA1ADRD4ADRA1DADRA1B | |
| SCHEMBL15709829 | 0.92 | HTR1A (1.00) | HTR1AADRA1ADRD4ADRA1DADRA1B | |
| SCHEMBL12677613 | 0.92 | HTR1A (1.00) | HTR1AADRA1ADRD4ADRA1DADRA1B | |
| SCHEMBL12677614 | 0.92 | HTR1A (1.00) | HTR1AADRA1ADRD4ADRA1DADRA1B | |
| SCHEMBL13295823 | 0.91 | HTR1A (0.85) | HTR1AADRA1ADRD4ADRA1DADRA1B | |
| SCHEMBL12677617 | 0.91 | HTR1A (0.85) | HTR1AADRA1ADRD4ADRA1DADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133663-A1 | NOVEL SYNTHESIS METHOD | GE HEALTHCARE LIMITED (GB) | 2015-05-14 | — | — | US | disclosed |
| US-20150133663-A1 | NOVEL SYNTHESIS METHOD | GE HEALTHCARE LIMITED (GB) | 2015-05-14 | — | — | US | disclosed |
| US-20150133663-A1 | NOVEL SYNTHESIS METHOD | GE HEALTHCARE LIMITED (GB) | 2015-05-14 | — | — | US | disclosed |
| US-20140140928-A1 | 5HT1A ANTAGONIST USEFUL FOR IN VIVO IMAGING | GE HEALTHCARE LIMITED (GB) | 2014-05-22 | — | — | US | disclosed |
| US-20140140928-A1 | 5HT1A ANTAGONIST USEFUL FOR IN VIVO IMAGING | GE HEALTHCARE LIMITED (GB) | 2014-05-22 | — | — | US | disclosed |
| US-20140140928-A1 | 5HT1A ANTAGONIST USEFUL FOR IN VIVO IMAGING | GE HEALTHCARE LIMITED (GB) | 2014-05-22 | — | — | US | disclosed |
| WO-2013041682-A1 | NOVEL SYNTHESIS METHOD | GE HEALTHCARE LIMITED (GB) | 2013-03-28 | — | — | WO | disclosed |
| US-20120136152-A1 | EFFICIENT SYNTHETIC METHOD OF 18F-MEFWAY PRECURSOR | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2012-05-31 | — | — | US | disclosed |
| US-20120136152-A1 | EFFICIENT SYNTHETIC METHOD OF 18F-MEFWAY PRECURSOR | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2012-05-31 | — | — | US | disclosed |
| US-7731940-B2 | N-(2-[4-(2-methoxyphenyl)piperazinyl]ethyl)-N-(2-pyridyl)-N-(4-18F-fluoro-methylcyclohexane)carboxamide, used for treating panic, bipolar or seizure disorders, and as a quantitative tool for measuring serotonin concentration in the brain | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-06-08 | — | — | US | disclosed |
| US-20070196271-A1 | COMPOSITIONS AND METHODS RELATED TO SEROTONIN 5-HT1A RECEPTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070196271-A1 | COMPOSITIONS AND METHODS RELATED TO SEROTONIN 5-HT1A RECEPTORS | HTR5A, HTR1A, HTR7 | HTR1A 2/4885ADRA1A 53/4885DRD4 77/4885 |
| US-20120136152-A1 | EFFICIENT SYNTHETIC METHOD OF 18F-MEFWAY PRECURSOR | FTO, SLC7A5, CYP3A5 | HTR1A 1516/4885ADRA1A 1746/4885DRD4 3040/4885 |
| US-20150133663-A1 | NOVEL SYNTHESIS METHOD | HTR1A, HTR5A, TPH1 | HTR1A 1/4885ADRA1A 137/4885DRD4 41/4885 |
| US-20140140928-A1 | 5HT1A ANTAGONIST USEFUL FOR IN VIVO IMAGING | HTR1A, HTR1E, HTR5A | HTR1A 1/4885ADRA1A 30/4885DRD4 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.